Symphogen A/S to Present Rozrolimupab (SYM001) Final Data at 2011 American Society of Hematology Meeting

COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen announced today that Phase 2 final data will be presented from an open-label, multi-center clinical trial evaluating the efficacy, safety, and tolerability of Rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune Thrombocytopenia (ITP) at the 53rd Annual Meeting of the American Society of Hematology (ASH) (http://www.hematology.org/Meetings/Annual-Meeting/) in San Diego, CA, US on December 12, 2011 from 3:45 to 4:00 PM. Final results will be presented in an oral session: “Disorders of Platelet Number or Function” with the title “Final results From a Phase II Trial with the First-in-Class Recombinant Polyclonal Antibody Product Rozrolimupab in Primary Immune Thrombocytopenia (ITP)” by professor Tadeusz Robak of University of Lodz, Poland.

Back to news